Crescent Biopharma (CBIO) Share-based Compensation (2013 - 2026)

Crescent Biopharma (CBIO) has 14 years of Share-based Compensation data on file, last reported at $4.1 million in Q1 2026.

• Share-based Compensation for Q1 2026 came in at $4.1 million, up 234.66% year-over-year; the trailing twelve-month figure through Mar 2026 was $16.2 million (up 344.7% YoY), and the FY2025 annual result was $13.3 million, up 183.13% from the prior year.
• Share-based Compensation declined to $4.1 million in Q1 2026 per CBIO's latest filing, from $4.7 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $5.3 million in Q2 2025 and troughed at $69000.0 in Q3 2024.
• A 5-year average of $1.7 million and a median of $1.1 million in 2022 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2024 and 2025: Share-based Compensation sank 92.23% in 2024, then soared 2778.26% in 2025.
• A 5-year view of Share-based Compensation shows it stood at $899201.0 in 2022, then advanced by 1.02% to $908371.0 in 2023, then gained by 24.84% to $1.1 million in 2024, then soared by 318.43% to $4.7 million in 2025, then dropped by 13.32% to $4.1 million in 2026.
• Business Quant data shows CBIO's Share-based Compensation at $4.1 million in Q1 2026, $4.7 million in Q4 2025, and $2.0 million in Q3 2025.